EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

The European Medicines Agency (EMA) has begun an accelerated review of Gilead’s Trodelvy for the treatment of advanced triple-negative breast cancer. ... Gilead is also testing Trodelvy’s potential in non-small cell lung cancer and metastatic

Setting up for success in a post-Brexit, post-pandemic Britain

and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead. ... With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

The two companies first announced their NASH collaboration in 2019. Gilead and Novo Nordisk have planned a new phase 2b trial in a bid to expand their clinical collaboration in ... The two companies first announced their collaboration in 2019, focused on

Yescarta gains first FDA approval for indolent follicular lymphoma

First CAR-T cell therapy to be approved in this indication. Gilead subsidiary Kite's Yescarta has been granted accelerated approval from the US Food and Drug Administration (FDA) for indolent

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]